Skip to main content
Delfa

← All assets

Gantenerumab

13 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

13

Ongoing

1

Recruiting

0

Completed

5

Sites

560

Countries

37

Endpoints

492

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 492 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2
1
Phase 2/3
3
Phase 3
7

Trials by status

Active, not recruiting
1
Completed
5
Terminated
7

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
106
Amyloid biomarkers
75
Other (unclassified)
62
Safety / tolerability / PK
44
Neuroimaging
38
Memory
32
Function / daily living
30
Tau biomarkers
28
Behavior / neuropsychiatric
26
Neurodegeneration biomarkers
16
Fluid / digital biomarkers
11
Disease progression
10
Caregiver / quality of life
8
Executive function / language
6

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 120 of 492 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Mini-Mental State Examination (MMSE)Cognition

25

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

20

ADAS-CogCognition

19

Neurofilament light (NfL)Neurodeg.

12

Amyloid PET CentiloidAmyloid

12

ADCS-Activities of Daily Living (ADCS-ADL)Function

10

ADAS-CogMemory

8

Neuropsychiatric Inventory (NPI)Behavior

6

Neuropsychiatric Inventory (NPI)Cognition

2

Phosphorylated tau 181 (p-tau181)Tau

2

Neurofilament light (NfL)Progression

2

ADAS-CogOther

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

13 of 13

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT04374253A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

Study partner/caregiver requiredPh 3Terminated268Mar 20231results
NCT03444870Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

prodromal ADPh 3Terminated172Dec 20225results
NCT03443973Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

prodromal ADPh 3Terminated155Sep 20225results
Scarlet RoadA Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease

Gantenerumab

Alzheimer’s disease

prodromal ADPh 3Completed139Sep 20205results
NCT02051608A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Gantenerumab

Alzheimer’s disease

Amyloid biomarker required (CSF)Ph 3Completed131Apr 20212results
SKYLINEA Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

Study partner/caregiver requiredPh 3Terminated63Mar 20232results
NCT04339413A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

-Ph 3Terminated56Jan 2023-results
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

E2814, Gantenerumab, Lecanemab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting38Apr 202815
NCT04592341A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Gantenerumab

Alzheimer’s disease

prodromal ADPh 2Terminated34Jan 2023-results
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Gantenerumab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Completed25Nov 201913results
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Gantenerumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Terminated17Oct 202313results
NCT00531804A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.

Gantenerumab

Alzheimer’s disease

Alzheimer's diseasePh 1Completed9Sep 2010-
NCT01656525A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

Gantenerumab

Alzheimer’s disease

Alzheimer's diseasePh 1Completed5Mar 2014-

Showing 1-13 of 13 trials